For the first time in its history, Medicare is going to cover weight loss drugs. Starting July 1, qualifying seniors can get Wegovi or ZepBound for just $50 per month through a new program. Medicare GLP-1 Bridge.
This is a huge deal. These drugs typically cost more than $1,000 per month at list price. And for decades, federal law prohibited Medicare from covering any drug prescribed solely for weight loss.
So $50 seems like a miracle. But before you call your doctor, you need to understand what you’re really signing up for.
Here are seven things every Medicare beneficiary should know before trusting the program.
1. You’re Probably Not Qualified
This is not a blanket benefit for every senior who wants to lose weight. The eligibility criteria are strict.
You’ll need a body mass index (BMI), which is a measure of body fat based on height and weight, of at least 27 combined with a qualifying medical condition such as prediabetes, a history of heart attack or stroke, or peripheral artery disease.
At higher BMI levels (30+), conditions such as heart failure, uncontrolled high blood pressure, chronic kidney disease or severe sleep apnea may make you eligible.
About 10% of Medicare beneficiaries are expected to be eligible, according to administration officials cited by CNBC. That’s a fraction of the approximately 67 million people enrolled in the program.
Your doctor will also need to submit a prior authorization through the central processor operated by the Centers for Medicare & Medicaid Services (CMS) – not your regular Part D plan. This is additional paperwork and may mean delays.
2. It only lasts for six months
The bridge program runs from July 1 to December 31, 2026. That is all. Six months.
After that, you must enroll in a Part D plan that participates in a long-term program called equilibrium modelWhich will launch in January 2027 and will run till 2031.
But there is a catch within the catch too. We’ll get to that next.
3. The future of this coverage hangs in the balance
To pursue the balance model in Medicare, at least 80% of Part D enrollment must be represented by applicable plans to participate. The application deadline was April 20, 2026, and CMS is expected to announce whether the deadline was met by April 30.
Here’s the problem: According to advisory boardMost Part D sponsors do not believe the 80% threshold will be met.
If not, there is no balance model in 2027. And that means millions of seniors who started GLP-1 medications under the bridge could lose access at the end of the year.
Think about that. You spend six months on a drug that’s working, your weight is losing, your health indicators are improving — and then on January 1, 2027, the rug is pulled.
4. Health insurers have serious doubts
The program isn’t the only one facing skepticism from actuaries. The insurance industry itself is raising red flags.
The Coalition of Community Health Plans publicly stated this Research has raised concerns About the side effects, risks, and long-term follow-up of GLP-1. This is a polite way of saying: “We are not sure these medications produce lasting results, and we are concerned about the cost.”
This is a legitimate concern. Research shows that patients who stop taking GLP-1 medications may gain weight rapidly. And insurers — who would bear the financial risk under the balance model — aren’t thrilled about covering a drug that patients may need indefinitely.
Some industry analysts have pointed out that if lower GLP-1 prices lead to widespread widespread use, Total spending on these drugs may still increaseEating up the plan budget.
5. Your $50 copayment will not count toward your Part D cap
Here’s a detail almost no one is talking about. The $50 you pay each month under the bridge does not count toward your Part D annual out-of-pocket cap, which is $2,100 in 2026.
This is because Bridge operates completely outside of normal Part D coverage. CMS runs the entire thing through a separate claims system. Your Part D plan has nothing to do with this.
So those GLP-1 payments won’t help you reach your out-of-pocket limits faster for other drugs you’re taking. It’s essentially a separate bill on top of everything else.
6. Low-income subsidies do not apply
If you qualify for Medicare’s Low-Income Subsidy program – also known as Extra Help – you’re accustomed to paying less on your prescriptions. under the bridge, That benefit does not apply For GLP-1 drugs.
This means that even beneficiaries who typically pay little or nothing for drugs must pay the full $50 monthly payment. For someone living on a fixed income, $50 a month – $300 over a six-month program – may not be manageable.
CMS has not addressed this gap.
7. You may have to change plans in 2027 to keep your medications
Even if the balance model launches, your current Part D plan may not participate. Participation is voluntary.
This means that to maintain your GLP-1 drug coverage in 2027, you may need to switch to a new Part D plan during open enrollment. And changing plans can have a cascading effect on coverage for every other drug you take.
Plans may also move out of the BALANCE model in future years. So you may change plans once, get settled, and then face the same disruption.
what should you do right now
Can’t wait to see how this plays out. If you’re on Medicare and are interested in GLP-1 coverage, take these steps now.
Talk to your doctor. Find out if you meet the BMI and medical criteria for the Bridge Program. Start documenting your conditions. This will be required for the prior authorization process.
Keep an eye out for an announcement on April 30th. CMS is expected to disclose whether enough Part D plans have signed up for the balance model to continue in 2027. This declaration determines whether this is a temporary experiment or a permanent benefit.
Review your Part D plan. If balance carry over, you’ll want to know if your plan is participating before open enrollment begins on October 15. Don’t wait until December to find out.
Consider the full cost picture. Even at $50 per month, that’s $300 in six months. And if you’re also paying for other Part D drugs, those costs add up quickly. Know what you can afford – and what Medicare won’t cover.
If you’re paying out of pocket for other prescriptions, it’s also worth knowing ways to cut those costs to free up space in your budget.
In the meantime, keep in mind that Ozempic, Vegovy and Rybelsus were among 15 drugs recently selected for Medicare price negotiations, which could lead to additional savings in 2027. And 10 other drugs have already become cheaper thanks to the first round of those negotiations.
Medicare covering weight loss drugs is historic. But don’t mistake a title for a guarantee. This program is temporary, limited and uncertain. The best thing you can do is go in with your eyes open.